Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study
article
OA: closed
CC0
⤵ 10 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This randomized, double-blind, multicenter, placebo-controlled study evaluated the efficacy, safety, and clinically recommended dose of dienogest for treating primary dysmenorrhea.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (33)
- Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK via openalex
- Diagnosis and initial management of dysmenorrhea. via openalex
- Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Early menstrual characteristics associated with subsequent diagnosis of endometriosis via openalex
- Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial via openalex
- Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- Influence of Dienogest on Ovulation in Young Fertile Women via openalex
- Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial via openalex
- Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—A systematic enquiry and overview via openalex
- Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis via openalex
- STUDIES IN THE INVOLVEMENT OF PROSTAGLANDINS IN UTERINE SYMPTOMATOLOGY AND PATHOLOGY via openalex
- Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy via openalex
- doi:10.1016/j.fertnstert.2011.02.045 via openalex
- doi:10.1136/bmj.332.7550.1134 via openalex
- doi:10.1093/humupd/dmv039 via openalex
- doi:10.2147/ijwh.s71906 via openalex
- doi:10.1136/bmj.d2139 via openalex
- doi:10.1111/1471-0528.12210 via openalex
- doi:10.1053/beog.1999.0018 via openalex
- doi:10.1136/bmj.d2151 via openalex
- doi:10.1111/j.1447-0578.2007.00189.x via openalex
- doi:10.1002/14651858.cd001751.pub3 via openalex
- doi:10.1002/14651858.cd002120.pub3 via openalex
- doi:10.1016/j.contraception.2006.12.008 via openalex
- W6603047530 via openalex
- doi:10.1111/jog.13406 via openalex
- doi:10.2147/ijwh.s107516 via openalex
- doi:10.2147/ijwh.s134576 via openalex
- W6642363463 via openalex
- W6676680339 via openalex
- doi:10.1080/13625187.2016.1239077 via openalex
Cited by (10)
- Dienogest Therapy Against the Combined Oral Contraceptive Pill in Deep Infiltrating Endometriosis Cases: A Systematic Review and Meta-Analysis 2025
- Comparative Study of 0.5 mg Dienogest Tablets (1 mg/Day) and Continuous Low-Dose Estrogen/Progestin for Dysmenorrhea: A Retrospective Analysis—Influence of Bleeding-Related Factors Such as Endometrial Polyps, Uterine Fibroids, and Adenomyosis 2025
- Efficacy of 0.5 mg Dienogest Tablets in Treating Premenstrual Syndrome-like Symptoms: A Comparative Study with a Low-Dose Estrogen–Progestin Combination 2024
- Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial (Preprint) 2024
- Assessing the impact of hormonal contraceptive use on menstrual health among women of reproductive age - a systematic review 2024
- Efficacy of Low-Dose Estrogen–Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis 2022
- Ovarian reserve may influence the outcome of bone mineral density in patients with long-term use of dienogest 2021
- Impact of 1.0 mg/Day Dienogest Treatment on Bone Metabolism Markers in Young Women with Dysmenorrhea 2021
- Primary dysmenorrhea: new dose of an old medicine offers more options 2020
- Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea 2020
Source provenance
- openalex
- last seen: 2026-05-11T06:18:49.075943+00:00
License: CC0
· commercial use OK